

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-95. (Cancelled)

Claim 96. (previously presented): An *ex vivo* method for downregulating CCR5 expression in a T cell comprising contacting the T cell with at least one bead said bead comprising an anti-CD28 antibody or antigen binding fragments and an anti-CD3 antibody or antigen binding fragments, both immobilized on said bead; and measuring the level of CCR5 RNA or protein expression in said contacted T cell, wherein the level of CCR5 expression in said contacted T cell is lower than the level of the CCR5 expression in a T cell not contacted with said bead.

Claim 97. (previously presented): A method for downregulating CCR5 RNA or protein expression in a T cell, comprising contacting the T cell *in vivo* with at least one bead said bead comprising an anti-CD28 antibody or antigen binding fragments and an anti-CD3 antibody or antigen binding fragments, both immobilized on said bead; and measuring the level of CCR5 RNA or protein expression in said contacted T cell, wherein the level of CCR5 RNA or protein expression in said contacted T cell is lower than the level of the CCR5 RNA or protein expression in a T cell not contacted with said bead.

Claim 98. (Cancelled)

Claim 99. (previously presented): The method of any one of claims 96 or 97, wherein the anti-CD3 antibody is an anti-human CD3 monoclonal antibody.

Claim 100. (previously presented): The method of any one of claims 96 or 97, wherein the anti-CD28 antibody is an anti-human CD28 monoclonal antibody.

Claim 101. (previously presented): The method of any one of claims 96 or 97, wherein the anti-CD3 antibody or antigen binding fragments and the anti-CD28 antibody or antigen binding fragments are coupled to the bead via a covalent modification.

Claim 102. (previously presented): The method of any one of claims 96 or 97, wherein the anti-CD3 antibody or antigen binding fragments and the anti-CD28 antibody or antigen binding fragments are coupled to the bead via an avidin-biotin complex.

Claim 103. (previously presented): The method of any one of claims 96 or 97, wherein the anti-CD3 antibody and the anti-CD28 antibody are directly coupled to the bead.

Claim 104. (previously presented): The method of any one of claims 96 or 97, wherein the bead is a biodegradable bead.

Claim 105. (previously presented): The method of any one of claims 96 or 97, wherein the bead is a magnetic bead.

Claim 106. (previously presented): The method of any one of claims 96 or 97, wherein the anti-CD28 antibody or antigen binding fragments and the anti-CD3 antibody or antigen binding fragments, are coupled to the same bead.

Claim 107. (previously presented): The method of any one of claims 96 or 97, wherein the T cells comprise HIV-infected T cells.